AJANTPHARM - Ajanta Pharma
📢 Recent Corporate Announcements
Ajanta Pharma Limited has scheduled an interaction with institutional investors and analysts on March 10, 2026. The company will be participating in the Investec India Promoter & Founder Conference 2026 held at Trident, BKC. The engagement will include both group and one-on-one meeting formats. Management has confirmed that all discussions will be based strictly on previously published information, ensuring no selective disclosure of material data.
- Participation in the Investec India Promoter & Founder Conference 2026 scheduled for March 10, 2026.
- Interaction format includes both group and one-on-one meetings with institutional investors.
- The meeting is set to take place at Trident, BKC, Mumbai.
- Company confirms that no unpublished price-sensitive information (UPSI) will be shared during the sessions.
Ajanta Pharma Limited has officially denied news reports claiming it plans to raise ₹2,000 crore to acquire Restaurant Brands Asia (RBA). The company clarified that the acquisition is being pursued independently by a section of the promoter group through Lenexis Foodworks Pvt. Ltd., and not by the listed entity. This clarification addresses a report in The Economic Times which incorrectly suggested the drugmaker was diversifying into the Quick Service Restaurant (QSR) sector. The management confirmed that Ajanta Pharma Limited is in no way involved in this transaction.
- Company denies raising ₹2,000 crore for the acquisition of Restaurant Brands Asia.
- Clarifies that the listed entity, Ajanta Pharma, is not a party to the QSR sector diversification.
- The acquisition is an independent move by the promoter group via Lenexis Foodworks Pvt. Ltd.
- This is a follow-up clarification to a similar denial issued by the company on January 20, 2026.
Ajanta Pharma Limited has officially released the written transcript of its earnings conference call for the third quarter ended December 31, 2025. The call, which took place on January 30, 2026, involved detailed discussions with analysts and institutional investors regarding the company's quarterly performance. This document provides a formal record of management's commentary on revenue drivers, operational margins, and strategic outlook. Investors can now access the full dialogue to understand the nuances of the company's growth trajectory in both domestic and international markets.
- Official transcript of the Q3 FY2025-26 earnings call held on January 30, 2026, is now available.
- The disclosure is made in compliance with Regulation 30 of SEBI (LODR) Regulations 2015.
- Provides detailed management insights into the performance for the October-December 2025 period.
- Includes the full Q&A session between company leadership and institutional analysts.
- Accessible via the company's website for comprehensive fundamental research.
Ajanta Pharma Limited has announced its participation in three major institutional investor conferences scheduled for February 2026. The company will attend Axis Capital's Flagship India Conference and the Nuvama India Conference on February 10, followed by the Kotak Flagship Conference on February 24. These meetings will consist of group and one-on-one interactions held in Mumbai. The company confirmed that all discussions will be based strictly on already published information.
- Participation in Axis Capital's Flagship India Conference on February 10, 2026, at Trident, BKC.
- Attendance at Nuvama India Conference 2026 on February 10, 2026, at Grand Hyatt, Santacruz.
- Scheduled meeting at Kotak Flagship Conference 2026 on February 24, 2026.
- Meetings will involve both group and one-on-one formats with institutional investors.
- Company confirms no unpublished price-sensitive information will be shared during these meets.
Ajanta Pharma Limited has officially denied media reports suggesting it was considering an acquisition of a stake in Restaurant Brands Asia (Burger King operator). The company clarified that neither the management nor the entity is involved in any discussions or negotiations regarding this transaction. This response follows a Reuters article dated January 19, 2026, which incorrectly linked the pharmaceutical firm to the Everstone stake sale. The company maintains that the rumors are baseless and it remains committed to its core operations.
- Ajanta Pharma issued a formal denial regarding the acquisition of any stake in Restaurant Brands Asia.
- The clarification was made under Regulation 30(11) of SEBI Listing Obligations and Disclosure Requirements.
- Management confirmed no discussions or proposals have been considered relating to the Burger King franchise.
- The company labeled the news reports appearing in Reuters and Economic Times as incorrect.
- Ajanta Pharma reaffirmed its adherence to high standards of corporate governance and timely disclosures.
Ajanta Pharma Limited has announced the incorporation of a new wholly owned subsidiary, Ajanta Pharma Ireland Ltd., based in Ireland. The new entity is established specifically to carry out the business of pharmaceutical products in the region. As a newly incorporated company, it currently has no turnover or historical financial data. This move signifies Ajanta Pharma's strategic intent to expand its operational footprint and market presence within the European pharmaceutical landscape.
- Incorporation of 'Ajanta Pharma Ireland Ltd.' as a 100% wholly owned subsidiary.
- The subsidiary is established in Ireland to focus on the pharmaceutical products business.
- The entity is a fresh incorporation with zero historical turnover or assets at this stage.
- The move is compliant with Regulation 30 of the SEBI Listing Regulations.
- Strategic expansion aimed at strengthening the company's international business operations.
Ajanta Pharma Limited has scheduled its board meeting on January 30, 2026, to approve the unaudited financial results for the third quarter of FY 2026. Following the board meeting, the company will host an earnings conference call at 16:30 hrs IST to discuss the financial performance with analysts and investors. The call will feature the leadership team and include a Q&A session. This is a routine regulatory filing providing the timeline for the company's quarterly performance update.
- Q3 FY 2026 unaudited financial results to be released on January 30, 2026.
- Earnings conference call scheduled for 16:30 hrs IST on the same day.
- Universal dial-in numbers provided are +91 22 6280 1542 and +91 22 7115 8372.
- Audio playback of the call will be available on the company's website 120 minutes after the call ends.
Ajanta Pharma has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that security certificates were mutilated and cancelled after verification, and the name of the depositories was updated in the register of members. This is a standard procedural filing required by Indian stock exchanges to ensure the integrity of shareholding records.
- Compliance certificate submitted for the quarter ended December 31, 2025
- Confirmation provided by Registrar and Share Transfer Agent, MUFG Intime India Private Limited
- Securities received for dematerialization were processed within prescribed timelines
- Mutilated certificates were cancelled and depository names substituted in the register of members
Ajanta Pharma Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's Q3 and nine-month financial results for the period ending December 31, 2025. The window will remain closed until 48 hours after the official declaration of these results. This is a standard regulatory procedure to prevent insider trading during the sensitive pre-earnings period.
- Trading window closure effective from Thursday, January 1, 2026.
- Closure pertains to the Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
- The window will reopen 48 hours after the financial results are declared to the exchanges.
- Compliance with SEBI (Prohibition of Insider Trading) Regulations and Ajanta's Code of Conduct.
Ajanta Pharma has entered an in-licensing agreement with Biocon to market Semaglutide, a high-growth GLP-1 therapy, across 26 countries in Africa, the Middle East, and Central Asia. The agreement provides Ajanta with exclusive marketing rights in 23 countries and semi-exclusive rights in 3 others. Commercialization is expected to commence in late 2026 or early 2027, following the expiry of product patents in March 2026. This move leverages Ajanta's existing infrastructure of over 2,000 medical representatives and 220+ brands in emerging markets.
- In-licensing agreement with Biocon for Semaglutide marketing in 26 emerging market countries.
- Exclusive rights secured for 23 countries and semi-exclusive rights for 3 countries.
- Commercial launch targeted for late 2026/early 2027 after patent expiry in March 2026.
- Ajanta reported FY2024-25 Revenue of Rs. 4,648 cr and a healthy 3-year PAT CAGR of 25%.
- Strategic entry into the blockbuster GLP-1 receptor agonist category to improve glycaemic control.
Financial Performance
Revenue Growth by Segment
India business grew 12% YoY to INR 432 Cr in Q2 FY26, outperforming the Indian Pharmaceutical Market (IPM) growth of 8% by 32%. Asia business grew 5% YoY to INR 310 Cr in Q2 FY26, with H1 FY26 sales at INR 614 Cr (up 7%). Africa business recorded sales of INR 221 Cr in Q2 FY26. US Generics is expected to deliver high-teen growth in the coming year.
Geographic Revenue Split
India contributes 32% of total revenue. Asia (Middle East, South-East, and Central Asia) and Africa (West and East Africa) represent the primary export markets. US Generics remains a selective play.
Profitability Margins
Gross margins stood at 77% for Q2 FY26 and 78% for H1 FY26, with a full-year guidance of 78% (+/- 1%). Profit After Tax (PAT) margin was 19% in Q2 FY26, increasing to 22% when excluding mark-to-market forex impacts. PAT grew 20% YoY to INR 260 Cr in Q2 FY26.
EBITDA Margin
Reported EBITDA margin was 24% in Q2 FY26 (INR 328 Cr, up 5% YoY). Excluding mark-to-market forex losses of INR 41 Cr, the adjusted EBITDA margin was 27% (INR 369 Cr, up 9% YoY). Management guides for a sustained EBITDA margin of 27% (+/- 1%).
Capital Expenditure
Not disclosed in available documents, though the company maintains 7 manufacturing plants and continues to invest in R&D and field force expansion.
Credit Rating & Borrowing
The company maintains a strong credit profile with a Return on Capital Employed (ROCE) of 30% and Return on Net Worth (RONW) of 25% as of H1 FY26. Specific interest rates are not disclosed, but finance costs were minimal at INR 3 Cr in Q2 FY26 (0% of revenue).
Operational Drivers
Raw Materials
Pharmaceutical active ingredients and excipients for specialty formulations. Cost of materials consumed was INR 217.60 Cr in Q2 FY26.
Capacity Expansion
The company operates 7 manufacturing plants located in Paithan, Chikalthana, Chitegaon, Waluj (Maharashtra), Dahej (Gujarat), Guwahati (Assam), and Pithampur (Madhya Pradesh). Specific MTPA capacity is not disclosed.
Raw Material Costs
Cost of Goods Sold (COGS) represented 23% of revenue in Q2 FY26 (INR 317 Cr) and 22% in H1 FY26 (INR 592 Cr). Procurement is managed to maintain a high gross margin of 78%.
Manufacturing Efficiency
The company focuses on specialty pharmaceutical formulations, outpacing IPM volume growth by 2x and new launch growth by 39%.
Logistics & Distribution
Other expenses, which include distribution and forex losses, were INR 392 Cr in Q2 FY26 (29% of revenue), up 11% YoY.
Strategic Growth
Expected Growth Rate
14%
Growth Strategy
Growth is driven by outpacing the IPM (currently by 32%), launching new products (10 in India and 13 in Asia during H1 FY26), and expanding the field force (personnel costs increased 21% due to MR additions). The company is targeting low-teen growth in Asia and high-teen growth in the US market for the next year.
Products & Services
Specialty pharmaceutical formulations primarily in chronic therapeutic segments (Ophthalmology, Dermatology, Cardiology, and Pain Management).
Brand Portfolio
Ajanta Pharma (Corporate Brand).
New Products/Services
Launched 10 new products in India (including one first-to-market) and 13 in Asia during H1 FY26. New launches outpaced the market by 39%.
Market Expansion
Focusing on high-potential chronic therapy markets in Asia (Middle East, SE Asia, Central Asia) and selective play in US Generics.
Market Share & Ranking
Ranked among the top 3-5 pharma companies in terms of margins; outpaces IPM growth (10% vs 8%).
External Factors
Industry Trends
The pharmaceutical industry is seeing a shift toward chronic therapies and specialty formulations. Ajanta is positioned as a specialty player, growing at 1.25x the market rate (10% vs 8% IPM).
Competitive Landscape
Faces intense competition and pricing pressure in both domestic and export markets from other generic pharmaceutical manufacturers.
Competitive Moat
Durable competitive advantage through branded generics in emerging markets, high ROCE (30%), and a lean, selective model in the US market. Sustainability is driven by consistent R&D and field force expansion.
Macro Economic Sensitivity
Sensitive to global healthcare spending and regulatory environments in the US and emerging markets.
Consumer Behavior
Increasing demand for chronic therapy medications globally due to aging populations and lifestyle changes.
Geopolitical Risks
Operations in Middle East and Africa expose the company to regional geopolitical instability and currency volatility.
Regulatory & Governance
Industry Regulations
Subject to USFDA and other national regulatory standards for manufacturing facilities. Compliance is critical for maintaining access to regulated markets.
Taxation Policy Impact
Effective tax rate was approximately 23.7% in Q2 FY26 (INR 81 Cr tax on INR 341 Cr PBT).
Legal Contingencies
Income Tax Authorities conducted search operations at certain premises of the company in August 2025. The outcome and potential financial liability are currently pending and not yet determined.
Risk Analysis
Key Uncertainties
Forex volatility (impacted margins by 3% in Q2), regulatory changes in drug pricing (DPCO in India), and the outcome of the August 2025 Income Tax search.
Geographic Concentration Risk
India accounts for 32% of revenue, with significant reliance on emerging markets in Asia and Africa.
Technology Obsolescence Risk
Risk is mitigated by continuous R&D in formulation development and a focus on chronic therapies which have longer product lifecycles.
Credit & Counterparty Risk
Trade receivables stood at INR 848.98 Cr as of September 30, 2025, up from INR 438.71 Cr in March 2025, indicating a significant increase in credit exposure.